Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1958 3
1960 1
1961 2
1963 2
1964 2
1965 4
1966 1
1967 1
1968 3
1969 1
1970 5
1971 4
1972 4
1973 2
1974 3
1975 4
1976 4
1977 2
1978 3
1980 1
1981 3
1982 2
1983 4
1985 3
1986 4
1987 2
1988 3
1989 5
1990 5
1991 1
1992 2
1993 2
1994 6
1995 1
1996 2
1997 4
1998 4
1999 6
2000 7
2001 11
2002 10
2003 12
2004 12
2005 12
2006 14
2007 11
2008 13
2009 14
2010 18
2011 23
2012 16
2013 30
2014 26
2015 32
2016 36
2017 36
2018 23
2019 40
2020 37
2021 38
2022 29
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

562 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.
Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, Rapoport AP, Sureda A, Jacobson CA, Farooq U, van Meerten T, Ulrickson M, Elsawy M, Leslie LA, Chaganti S, Dickinson M, Dorritie K, Reagan PM, McGuirk J, Song KW, Riedell PA, Minnema MC, Yang Y, Vardhanabhuti S, Filosto S, Cheng P, Shahani SA, Schupp M, To C, Locke FL; ZUMA-7 Investigators; Kite Members. Westin JR, et al. N Engl J Med. 2023 Jul 13;389(2):148-157. doi: 10.1056/NEJMoa2301665. Epub 2023 Jun 5. N Engl J Med. 2023. PMID: 37272527 Clinical Trial.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S, Watts NB, Brandi ML, Peters E, Guise T, Eastell R, Cheung AM, Morin SN, Masri B, Cooper C, Morgan SL, Obermayer-Pietsch B, Langdahl BL, Al Dabagh R, Davison KS, Kendler DL, Sándor GK, Josse RG, Bhandari M, El Rabbany M, Pierroz DD, Sulimani R, Saunders DP, Brown JP, Compston J; International Task Force on Osteonecrosis of the Jaw. Khan AA, et al. Among authors: davison ks. J Bone Miner Res. 2015 Jan;30(1):3-23. doi: 10.1002/jbmr.2405. J Bone Miner Res. 2015. PMID: 25414052 Free article. Review.
Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.
Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, Rejnmark L, Thakker R, D'Amour P, Paul T, Van Uum S, Shrayyef MZ, Goltzman D, Kaiser S, Cusano NE, Bouillon R, Mosekilde L, Kung AW, Rao SD, Bhadada SK, Clarke BL, Liu J, Duh Q, Lewiecki EM, Bandeira F, Eastell R, Marcocci C, Silverberg SJ, Udelsman R, Davison KS, Potts JT Jr, Brandi ML, Bilezikian JP. Khan AA, et al. Among authors: davison ks. Osteoporos Int. 2017 Jan;28(1):1-19. doi: 10.1007/s00198-016-3716-2. Epub 2016 Sep 9. Osteoporos Int. 2017. PMID: 27613721 Free PMC article. Review.
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.
Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Martin Garcia-Sancho A, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, Cheng P, To C, Kersten MJ. Elsawy M, et al. Among authors: davison k. Blood. 2022 Nov 24;140(21):2248-2260. doi: 10.1182/blood.2022015478. Blood. 2022. PMID: 35839452 Free PMC article. Clinical Trial.
Autoimmunity in psychiatry.
Davison K. Davison K. Br J Psychiatry. 2012 May;200(5):353-5. doi: 10.1192/bjp.bp.111.104471. Br J Psychiatry. 2012. PMID: 22550326
Kurt Schapira.
Davison K, McClelland H, Kerr A, Schapira M. Davison K, et al. BMJ. 2017 Jan 30;356:j499. doi: 10.1136/bmj.j499. BMJ. 2017. PMID: 28137770 No abstract available.
562 results